Welcome to LookChem.com Sign In|Join Free

CAS

  • or

191033-19-9

Post Buying Request

191033-19-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

191033-19-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 191033-19-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,1,0,3 and 3 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 191033-19:
(8*1)+(7*9)+(6*1)+(5*0)+(4*3)+(3*3)+(2*1)+(1*9)=109
109 % 10 = 9
So 191033-19-9 is a valid CAS Registry Number.

191033-19-9Relevant articles and documents

Leveraging the cruzain S3 subsite to increase affinity for reversible covalent inhibitors

Cianni, Lorenzo,Sartori, Geraldo,Rosini, Fabiana,De Vita, Daniela,Pires, Gabriel,Lopes, Bianca Rebelo,Leit?o, Andrei,Burtoloso, Antonio C.B.,Montanari, Carlos A.

, p. 285 - 292 (2018)

Cruzain is the major cysteine protease of Trypanosoma cruzi, the etiological agent of Chagas disease. Reversible covalent cruzain inhibitors can block the steps of cell differentiation in the parasite and kill the organism. To this end, the description of

Mapping the s1 and s1’ subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents

Cianni, Lorenzo,Lemke, Carina,Gilberg, Erik,Feldmann, Christian,Rosini, Fabiana,Rocho, Fernanda Dos Reis,Ribeiro, Jean F. R.,Tezuka, Daiane Y.,Lopes, Carla D.,de Albuquerque, Sérgio,Bajorath, Jürgen,Laufer, Stefan,Leit?o, Andrei,Gütschow, Michael,Montanariid, Carlos A.

, (2020/04/24)

The cysteine protease cruzipain is considered to be a validated target for therapeutic intervention in the treatment of Chagas disease. A series of 26 new compounds were designed, synthesized, and tested against the recombinant cruzain (Cz) to map its S1/S1′ subsites. The same series was evaluated on a panel of four human cysteine proteases (CatB, CatK, CatL, CatS) and Leishmania mexicana CPB, which is a potential target for the treatment of cutaneous leishmaniasis. The synthesized compounds are dipeptidyl nitriles designed based on the most promising combinations of different moieties in P1 (ten), P2 (six), and P3 (four different building blocks). Eight compounds exhibited a Ki smaller than 20.0 nM for Cz, whereas three compounds met these criteria for LmCPB. Three inhibitors had an EC50 value of ca. 4.0 μM, thus being equipotent to benznidazole according to the antitrypanosomal effects. Our mapping approach and the respective structure-activity relationships provide insights into the specific ligand-target interactions for therapeutically relevant cysteine proteases.

Experimental study and computational modelling of cruzain cysteine protease inhibition by dipeptidyl nitriles

Dos Santos, Alberto Monteiro,Cianni, Lorenzo,De Vita, Daniela,Rosini, Fabiana,Leit?o, Andrei,Laughton, Charles A.,Lameira, Jer?nimo,Montanari, Carlos A.

, p. 24317 - 24328 (2018/10/05)

Chagas disease affects millions of people in Latin America. This disease is caused by the protozoan parasite Trypanossoma cruzi. The cysteine protease cruzain is a key enzyme for the survival and propagation of this parasite lifecycle. Nitrile-based inhib

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 191033-19-9